Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag Inks Central, Eastern European Distribution Deal for GI MDx Line

NEW YORK (GenomeWeb) – Finnish molecular diagnostics firm Mobidiag announced yesterday that it has signed an agreement making Austria's Biomedica Medizinprodukte the exclusive distributor of its Amplidiag in vitro diagnostic products in Central and Eastern Europe.

The Amplidiag line includes PCR-based tests for various gastrointestinal infections including two CE-IVD marked assays — Bacterial GE, which detects Campylobacter, Salmonella, Shigella, Yersinia, and five different Escherichia coli pathotypes; and Amplidiag C. difficile+27 for identifying toxin-producing Clostridium difficile — as well as the Amplidiag Easy automated platform that runs the tests. The firm also sells Amplidiag tests for H. pylori and stool parasites, and CarbaR+VRE, which identifies five major carbapenemase groups and two vancomycin resistance markers.

Under the terms of the deal, Biomedica will handle distribution for the products in Austria, Bosnia & Herzegovina, Bulgaria, Croatia, the Czech Republic, Hungary, Macedonia, Poland, Romania, Serbia, Slovakia, and Slovenia. Additional terms were not disclosed.

"Since Mobidiag's inception, we have been focusing our activity towards [the] Nordic region and France mainly," Mobidiag CEO Tuomas Tenkanen said in a statement. "We are very pleased today to expand Amplidiag accessibility to Central and Eastern Europe with the support of our partner, Biomedica Medizinprodukte."

In June, Mobidiag inked a deal with Isogen Life Sciences for Amplidiag distribution in Belgium, the Netherlands, Luxembourg, and Spain. Last year, the company made Unilabs its Amplidiag distributor in Sweden and Norway.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.